SPECIAL NOTICE
Q -- Southern Community Cohort Study samples for a multi-ancestry genome-wide association study of lymphoid malignancies
- Notice Date
- 8/2/2021 2:30:07 PM
- Notice Type
- Special Notice
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- NIH National Cancer Institute Rockville MD 20850 USA
- ZIP Code
- 20850
- Solicitation Number
- 75N91021Q00202
- Response Due
- 8/9/2021 12:00:00 PM
- Archive Date
- 08/24/2021
- Point of Contact
- Megan Kisamore, Phone: 2402765261
- E-Mail Address
-
megan.kisamore@nih.gov
(megan.kisamore@nih.gov)
- Description
- 1.0�� �DESCRIPTION The Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute (NCI), Division of Cancer Epidemiology & Genetics (DCEG), Occupational and Environmental Epidemiology Branch (OEEB) plans to procure, on a sole source basis, samples for a multi-ancestry genome-wide association study of lymphoid malignancies from Vanderbilt University Medical Center, 1161 21ST Avenue S Ste. D3300 Mcn, Nashville, TN 37232. The response close date of the notice for this requirement is in accordance with FAR 5.203(b). This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority in FAR Part 13.106-1(b)(1); and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 541380 and the small business size standard is $16.5 million. � It has been determined there are no opportunities to acquire green products or services for this procurement.� 2.0�� �BACKGROUND The Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute (NCI), Division of Cancer Epidemiology & Genetics (DCEG), Occupational and Environmental Epidemiology Branch (OEEB) requires samples from the Southern Community Cohort Study (SCCS).� There are over fifty different lymphoid malignancies (LM); however, the etiology of many lymphoid malignancies, especially rare subtypes, is largely unknown. Both environmental and genetic factors are thought to contribute to the risk of LM, some environmental risk factors being more strongly associated with some subtypes and others having a larger genetic component. NCI has a long history of conducting research on environmental and genetic risk factors for LM. As part of the InterLymph consortium, DCEG/OEEB previously conducted several large candidate-gene based studies, evaluations of lifestyle and environmental risk factor hypotheses, and analyses of gene-environment interactions for non-Hodgkin lymphoma (NHL). More recently, DCEG/OEEB conducted a large genome-wide association study (GWAS) of NHL in populations of European ancestry from 22 studies from the InterLymph and NCI Cohort consortia and identified over forty new genetic loci.� DCEG/OEEB is currently expanding a previous study to conduct a multi-ancestry genome-wide association study for LM using cases and controls from multiple institutions, including the Southern Community Cohort Study. This study will comprise cases and controls of European and non-European ancestry, including African, Asian and Latino/Hispanic ancestry. The Southern Community Cohort Study has a large collection of prospectively collected germline DNA samples from African Americans, making it a valuable component to this pooled GWAS effort. The inclusion of cases from this study is critical to strengthen the power of the study to detect genetic variants related to the risk of LM subtypes, especially for African Americans. African Americans have an increased risk of multiple myeloma and T-cell lymphoma compared to non-Hispanic Caucasians in the U.S., but the reasons for this disparity are unknown.� 2.1�� �OBJECTIVE The objective of this procurement is to obtain DNA samples and phenotype data from LM cases and controls collected within the Southern Community Cohort Study for a multi-ancestry genome-wide association study of lymphoid malignancies.� 3.0�� �SCOPE This purchase order includes the procurement of 1000 DNA specimens/samples from the Southern Community Cohort Study. Of the 1000 samples, 670 samples shall be requisitioned, and have DNA extracted and aliquoted. The remaining 330 samples shall be requisitioned and aliquoted only. In section 4.0 below, the required samples are divided into cases controls and quality control samples (485 cases + 485 controls + 30 QC samples = 1000 samples). The Contractor shall ship the samples and select covariate data to NCI. �All shipping fees shall be included in the award. 4.0�� �PURCHASE ORDER REQUIREMENTS The following tasks are required: 4.1�� �The Contractor shall identify 485 LM cases, 485 controls, and 30 quality control duplicates with DNA or DNA source (e.g., buccal or blood specimen) for the study. 4.2�� �For subjects without DNA available (n=670), the Contractor shall extract DNA from blood or buccal samples.� 4.3�� �The Contractor shall quantify the DNA by PicoGreen or similar technique and aliquot 1,000 DNA specimens for the study. 4.4�� �A total of 500 nanograms (or approved amount by the SCCS) of native genomic DNA containing a concentration of 50-80 ng/ul as quantified by PicoGreen or similar technique in a minimum volume of 25 ul shall be aliquoted for each subject.� 4.5�� �Samples shall be placed in barcode vials on dry ice and shipped to the NCI DNA Extraction and Staging Laboratory. �The shipment of specimens shall occur on either a Monday, Tuesday or Wednesday only via same day or overnight delivery. The Contractor shall provide tracking information to the NCI Technical Point of Contact.� 4.6�� �Prior to shipment, the Contractor shall provide to NCI a specimen manifest and phenotype data for the samples. �Phenotype data (e.g., age, sex, case-control status, etc.) shall be provided for the subjects. All data shall be coded and shall not contain any personally identifiable information (PII).� 4.7�� �Contractor shall assist in answering and resolving sample-related questions as they arise. 5.0�� �TYPE OF ORDER This is a firm fixed price purchase order.� 6.0�� �NON-SEVERABLE SERVICES The services specified in each contract line item (CLIN) have been determined to be non-severable services - a specific undertaking or entire job with a defined end product of value to the Government. 7.0�� �PERIOD OF PERFORMANCE Period of performance shall be 12 months from the date of award. 8.0�� �PLACE OF PERFORMANCE All work shall be performed at the Contractor�s facility. 9.0�� �REPORT(S)/DELIVERABLES AND DELIVERY SCHEDULE All written deliverables (e.g. specimen manifest and phenotype data) shall be sent electronically to the NCI Technical Point of Contact (TPOC), TBD at award, in a Microsoft compatible format, such as Microsoft Excel or text file. The TPOC shall review the contents of the deliverables. If no comments or requests for revisions are provided within 30 business days, the deliverables shall be considered acceptable. All DNA specimens shall be sent directly the NCI DNA Extraction and Staging Laboratory (DESL) for sample handling and processing. In conjunction with the laboratory, the NCI TPOC shall review the quality and quantity of the samples received. If no comments or requests are provided within 30 business days, the specimens shall be considered acceptable. All deliverables shall be sent per the following deliverable schedule: DELIVERABLE� /� DELIVERABLE DESCRIPTION / FORMAT REQUIREMENTS� /� DUE DATE Task 4.1 and Task 4.7:� Emails or phone calls with the NCI TPOC to discuss sample processing and aliquoting, and, after receipt of samples to assist in answering and resolving sample-related questions as they arise.� Due:�As needed Task 4.5:� Shipment of DNA samples. Due: no later than 30 business days prior to the purchase order expiration date. Task 4.6:��Excel spreadsheet containing the specimen manifest. Due: 5 business days prior to the shipment of samples. Task 4.6:� Excel spreadsheet or text file with phenotype data. Due:�5 business days prior to the shipment of samples. 10.0�� �UNIQUE QUALIFICATIONS OF THE CONTRACTOR The Southern Community Cohort Study (SCCS) was funded by the National Cancer Institute and initiated in 2001. Approximately 85,000 adults in the southeastern United States were enrolled in the study. Biological specimens were collected at enrollment. The SCCS has followed the subjects for cancer incidence and mortality since enrollment. The SCCS has among the highest representation of African Americans (two-thirds) among existing U.S. cohorts, and a large biorepository that can be utilized by researchers to address scientific questions about the causes of cancer. The SCCS is unique, as most cohort studies in the United States are predominantly Caucasian. In addition, it is extremely difficult to find prospectively collected biospecimens from African Americans who have been diagnosed with a lymphoid malignancy. Over the follow-up period, the SCCS has accumulated approximately 485 lymphoid malignancy cases with DNA. Therefore, the prospectively collected DNA samples and phenotype data collected in the Southern Community Cohort Study are a critical contribution to the DCEG/OEEB�s multi-ancestry genome-wide association study to ensure the study will have sufficient statistical power to evaluate lymphoid malignancies in African Americans. The required DNA samples and phenotype data from the Southern Community Cohort Study are located at Vanderbilt University Medical Center. Vanderbilt University Medical Center controls access to the Southern Community Cohort Study biorepository and is the only center that can provide specimens from this study. 11.0�� �SUBMISSION INSTRUCTIONS This notice is not a request for competitive quotations. However, if any interested party believes it can meet the above requirements, it may submit a proposal or quote for the Government to consider. The response and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. �All responses and questions must be sent via email to Contracting Officer, Megan Kisamore, at megan.kisamore@nih.gov by no later than 3:00 PM EST, on Monday, August 9, 2021 (8/9/21). A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, Contractors must be registered and have valid certification through SAM.gov. Reference: 75N91021Q00202 on all correspondence.
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/bc505f9850ce4aa6bbe3e7ea1f1d1c4c/view)
- Record
- SN06080932-F 20210804/210802230116 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |